GlassScriptPhysician profile
Matthew K Jenson
NPI 1063917243
$12,467.88
in general payments reported to CMS, 2019-2025
52 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $3,145 · 2023: $3,720 · 2024: $2,530 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,448 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,447.76 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,596.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,082.47 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $1,034.43 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $999.34 | 2021-2025 | |
| Amgen INC. | $910.78 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $810.30 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $464.10 | 2021-2023 | Breztri, Lokelma, Farxiga |
| Almatica Pharma LLC | $356.04 | 2022-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $316.89 | 2021-2025 | Trintellix |
| Gilead Sciences, INC. | $288.23 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.96 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $256.03 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $255.82 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $234.10 | 2021-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $215.47 | 2021-2024 | Xarelto |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $203.43 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Bayer Healthcare Pharmaceuticals INC. | $202.87 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $181.65 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.00 | 2021-2025 | Jardiance |
| Ironshore Pharmaceuticals INC. | $167.15 | 2022-2023 | Jornay Pm |
| Sumitomo Pharma America, INC. | $162.82 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $148.45 | 2023-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $148.24 | 2022 | |
| Lundbeck LLC | $141.25 | 2023-2025 | Rexulti, Vyepti |
| Abbott Laboratories | $137.94 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Freestyle Libre |
| Neurocrine Biosciences, INC. | $133.90 | 2024-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $125.47 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $125.28 | 2021-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Lexicon Pharmaceuticals, INC. | $121.71 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $119.92 | 2021-2025 | Eliquis |
| Acadia Pharmaceuticals INC | $101.73 | 2021-2023 | Nuplazid |
| Covis Pharma Gmbh | $99.59 | 2022-2023 | |
| Amarin Pharma, INC. | $98.07 | 2021-2022 | |
| Alkermes, INC. | $83.88 | 2023 | Aristada, Lybalvi |
| Exact Sciences Corporation | $80.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $78.66 | 2022-2023 | Ztlido |
| Alexion Pharmaceuticals, INC. | $77.01 | 2023-2024 | Strensiq |
| Axsome Therapeutics, INC. | $75.92 | 2024-2025 | Auvelity |
| Dexcom, INC. | $45.69 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $40.96 | 2023 | |
| Esperion Therapeutics, INC. | $38.54 | 2021 | |
| Mallinckrodt Hospital Products INC. | $38.51 | 2025 | Acthar |
| Phathom Pharmaceuticals, INC. | $36.22 | 2024 | Voquezna |
| Bausch Health US, LLC | $32.74 | 2022 | |
| Bioventus LLC | $23.32 | 2024 | Supartz Fx Sodium Hyaluronate |
| Ethicon US, LLC | $21.82 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.20 | 2021 | |
| Vanda Pharmaceuticals INC. | $21.03 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $20.62 | 2024 | Arexvy, Shingrix |
| Xeris Pharmaceuticals, INC. | $19.21 | 2023 | Gvoke Hypopen |
| Eisai INC. | $14.16 | 2022 | |
| Allergan, INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.